Sinotherapeutics Inc. (SHA:688247)

Market Cap	4.83B
Revenue (ttm)	513.23M
Net Income (ttm)	119.13M
Shares Out	449.00M
EPS (ttm)	0.26
PE Ratio	41.36
Forward PE	n/a
Dividend	0.05 (0.48%)
Ex-Dividend Date	Jun 27, 2025

Volume	4,172,159
Average Volume	3,716,300
Open	10.55
Previous Close	10.74
Day's Range	10.29 - 10.60
52-Week Range	8.49 - 14.00
Beta	0.10
RSI	45.21
Earnings Date	Oct 27, 2025

About Sinotherapeutics

Sinotherapeutics Inc., a specialty pharmaceutical company, develops generic and formulation products in China. It offers posaconazole delayed-release tablets, ursodeoxycholic acid capsules, bupropion hydrochloride extended-release tablets, paroxetine extended-release tablets, sevelamer carbonate tablets, and propafenone hydrochloride extended-release capsules. The company provides CRO/CDMO services including pre-formulation study, formulation and process development, clinical sample manufacturing, NDA registration batch manufacturing, quality s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 312
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688247

Financial Performance

In 2024, Sinotherapeutics's revenue was 511.62 million, an increase of 70.61% compared to the previous year's 299.87 million. Earnings were 127.70 million, an increase of 109.09%.